CYTK stock forecast, quote, news & analysis
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more
Why Cytokinetics (CYTK) Stock Is Down -10.4% in the Last 30 Days
Key Takeaways
- 30-day performance: CYTK declined about 10.4% from $81.93 on July 14, 2026, to $73.45 on August 13, 2026.
- Earnings overhang: Second-quarter results beat consensus revenue and EPS estimates, but a wider net loss and higher full-year expense guidance pressured the stock.
- Launch progress: MYQORZO (aficamten) generated $25.3 million in Q2 2026 net product revenue, supported by U.S. demand and the initial Germany launch.
- Quarterly context: The stock is down about 6.6% over the broader three-month window, even after positive ACACIA-HCM data and a 52-week intraday high in late June.
- Key watch items: The planned Q4 2026 sNDA filing for non-obstructive HCM, European commercial execution, and expense and cash trends are central to the outlook.
Cytokinetics (CYTK) Company Overview and Market Position
Cytokinetics, Incorporated is a specialty cardiology-focused biopharmaceutical company that develops muscle biology-directed therapies. Its lead commercial product, aficamten, is sold as MYQORZO and is approved for adults with symptomatic obstructive hypertrophic cardiomyopathy in the United States, the European Union, and China. The company is also developing aficamten for non-obstructive HCM and advancing earlier-stage muscle biology programs.
Investors follow CYTK primarily for MYQORZO launch execution, label-expansion opportunities, and the company's ability to convert clinical data into commercial revenue while managing a development-stage cost base.
Cytokinetics (CYTK) Stock Price Performance: Last 30 Days vs. Quarter
Based on available closing prices, CYTK ended August 13, 2026, at $73.45. Thirty calendar days earlier, on July 14, 2026, the stock closed at $81.93. That translates to a decline of about 10.4%.
Over the broader quarter, the stock has also pulled back: from a close of $78.64 on May 14, 2026, to $73.45 on August 13, 2026, CYTK declined about 6.6%. The three-month period was volatile, with a sharp rally in early May after ACACIA-HCM data and a 52-week intraday high of $88.31 on June 30, followed by a steady give-back into August.
What Drove CYTK Stock Price in the Last 30 Days
The main catalyst was the second-quarter earnings report released August 6, 2026. CYTK reported total revenue of $28.6 million, above consensus expectations near $17.6 million, and a net loss of $1.50 per share, narrower than the roughly $1.63 loss analysts anticipated. However, total revenue declined from $66.8 million in the prior-year quarter, when collaboration milestone revenue was recorded, and net loss widened from $134.4 million to $198.8 million.
Management also raised full-year 2026 combined R&D and SG&A expense guidance to $860 million to $890 million, from $830 million to $870 million, citing commercial-readiness investments. The shares closed at $81.37 on August 6 and fell about 5.7% to $76.76 on August 7, with additional selling in subsequent sessions.
Other factors added to the pullback. The stock had reached a 52-week intraday high of $88.31 on June 30, leaving it vulnerable to profit-taking. Regulatory progress, including UK approval of MYQORZO, provided a positive fundamental update but did not offset the post-earnings pressure. SEC filings also showed insider selling and some institutional repositioning, which contributed to cautious sentiment.
What Drove CYTK Stock Performance Over the Last Quarter
The defining event of the quarter was the positive Phase 3 ACACIA-HCM readout for aficamten in symptomatic non-obstructive HCM. On May 5, 2026, the company announced the trial met both dual primary endpoints, and CYTK shares jumped from a prior close of $66.05 to close at $77.09. The result supports a potential label expansion into a patient population with no approved therapies that directly target the underlying hypercontractility.
Commercial execution also advanced during the quarter. MYQORZO net product revenue reached $25.3 million in Q2 2026, with U.S. demand and the first shipments in Germany. A May public offering generated approximately $760 million in net proceeds, lifting cash and investments to about $1.7 billion, though it also increased the share count. Those positives were partially offset by widening losses, higher spending guidance, insider sales, and the broader pullback from late-June highs.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only top-performing and most relevant bots appear in this section. The featured bots vary by strategy, timeframe, and performance metrics, giving traders a way to compare different automated approaches. Monitoring the page can help traders identify currently favored AI strategies and assess whether any align with their own research process.
CYTK Stock Forecast Drivers: What Investors Should Watch Next
- Regulatory and clinical milestones: The company has targeted a supplemental New Drug Application filing for aficamten in non-obstructive HCM in Q4 2026. Full ACACIA-HCM data presentations and regulatory interactions will be important.
- MYQORZO commercial execution: U.S. prescription trends, patient access, European launches, and reimbursement decisions will show whether the obstructive HCM launch can scale.
- Financial trajectory: Investors are likely to monitor cash burn, full-year expense guidance, and whether product revenue growth narrows the gap with operating costs.
- Analyst and institutional sentiment: Price-target revisions and institutional positioning may continue to influence trading after the post-earnings reset.
- Biotech sector conditions: Broader market risk appetite, healthcare policy developments, and clinical-stage biotech sentiment remain relevant external factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CYTK in downward trend: price dove below 50-day moving average on August 07, 2026
CYTK moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend. In of 65 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for CYTK crossed bearishly below the 50-day moving average on August 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CYTK entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 21, 2026. You may want to consider a long position or call options on CYTK as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on August 21, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (140.845) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in discovery and development of small molecule drug therapeutics
Industry Biotechnology